Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

BACKGROUND: We present the 2-year results of a randomised trial comparing 4- versus 12-weekly bone-targeting agents (BTAs) in patients with bone metastases from breast or castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: Patients with bone metastases from breast or CRPC, who were go...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemons, Mark, Liu, Michelle, Stober, Carol, Pond, Gregory, Jemaan Alzahrani, Mashari, Ong, Michael, Ernst, Scott, Booth, Christopher, Mates, Mihaela, Abraham Joy, Anil, Aseyev, Olexiy, Blanchette, Phillip, Vandermeer, Lisa, Tu, Megan, Thavorn, Kednapa, Fergusson, Dean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449269/
https://www.ncbi.nlm.nih.gov/pubmed/34567960
http://dx.doi.org/10.1016/j.jbo.2021.100388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449269/
https://www.ncbi.nlm.nih.gov/pubmed/34567960
http://dx.doi.org/10.1016/j.jbo.2021.100388

Ejemplares similares